• Immune hemolytic anemia and chronic active hepatitis developed concurrently in a 76-year-old man after prolonged therapy with methyldopa. Both complications disappeared following cessation of treatment with the offending drug and a short course of a high-dose corticosteroid (prednisone). Inhibition of T-suppressor lymphocyte function by methyldopa may be instrumental in the emergence of autoimmune complications following usage of the drug.
(Arch Intern Med 1983;143:592-593)
Shalev O, Mosseri M, Ariel I, Stalnikowicz R. Methyldopa-Induced Immune Hemolytic Anemia and Chronic Active Hepatitis. Arch Intern Med. 1983;143(3):592-593. doi:10.1001/archinte.1983.00350030206040